4月25日,派格生物医药(苏州)股份有限公司正式通过港交所聆讯,计划登陆港股市场。中金公司担任独家保荐人。这是派格生物第二次向港交所递交申请,此前其曾尝试科创板上市但未能成功。派格生物成立于2008年,专注于自主研发慢性病创新疗法,特别是肽和小分子药物的开发,核心领域为代谢紊乱。其核心产品PB-119是一款接近商业化的长效GLP-1受体激动剂,主要用于治疗T2DM及肥胖症。截至目前,派格生物已完成...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.